BioWorld Asia

May 24, 2006

U3 Pharma Raises EUR 27M For Preclinical Cancer Products

U3 Pharma AG raised €27 million (US$34.7 million) to accelerate development of its pipeline of targeted therapies, designed to modulate signal transduction pathways in cancer. (BioWorld International) Read More

Vaccine Awards To Come, But Patent Issues Remain

Rare Inherited Skin Tumor Points To Oncogene Control Mechanism

Further Labeling Controls Foreseen For EU GM Crops

MorphoSys Adds As Partner For HuCal Schering-Plough

BioAlliance Starting Phase III Trial, Exploring Opportunities

New Irish Research Initiative Puts Focus On Universities

After Merger With Proteom, Amura Wants Deals, Money

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...

Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

AI drug developer Insilico to raise $292 million in Hong Kong IPO

BioWorld

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...